Influenza Vaccine, Non Small Cell Lung Cancer
Conditions
Keywords
Non-Small Cell Lung Cancer, Influenza Vaccine, PD-1 Receptor, Programmed Cell Death 1 Ligand 1
Brief summary
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
Detailed description
Lung cancer is one of the most prevalent cancers in the world. Among them, non-small cell lung cancer (NSCLC) accounts for about 85%. Immune checkpoint inhibitors such as programmed death 1(PD-1) and PD-L1 are new treatments for NSCLC. About 290,000 to 650,000 people die from respiratory illnesses caused by seasonal flu all over the world. Cancer patients are one of the high-risk groups of influenza. Although the United States, Britain, Australia have issued guidelines recommending that cancer patients be vaccinated against influenza every year, due to concerns about the immune effect and safety of flu vaccination for cancer patients, multiple countries including China have not included cancer patients into priority influenza vaccination populations. Therefore, how to further prove the immunogenicity and safety of influenza vaccine in NSCLC patients is the key to promote influenza vaccines in NSCLC patients. This study will recruit 130 patients with NSCLC who have been treated with PD-1 / PD-L1 inhibitors for 6 months or more and 30 healthy participants. Among them, 100 NSCLC patients and 30 healthy participants will be intramuscularly inactivated with a trivalent influenza vaccine during the influenza seasons 2020-21 and 2021-22. Vaccinated participants' peripheral blood samples were collected at day0, 12 hours, day1, 2, 7, 21, 30, 60 and 6 months after vaccination. The influenza specific antibody titers, inflammatory chemokines and cytokines, antibody-dependent cellular cytotoxicity (ADCC) activity, T lymphocytes activity and the proportions of different T cells subgroups will be measured to evaluate the participants' immune response to the vaccine. In addition, for the subjects receiving the vaccine, the study will also group by age to compare the differences in immune effects between subjects aged 18-65 and subjects over 65. At last, this project will compare immune-related adverse events (irAEs) that occurred after receiving PD-1 / PD-L1 inhibitor therapy and survival time between NSCLC patients who receive influenza vaccine and those who do not receive influenza vaccine.
Interventions
Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
BIOLOGICALInactivated trivalent influenza vaccine
Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
Sponsors
The University of Hong Kong
Shanghai Pulmonary Hospital, Shanghai, China
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. NSCLC patients were diagnosed with clear pathological classification and receive PD-1 / PD-L1 inhibitor treatment during this project. 2. NSCLC patients have the exact start and end time of PD-1 / PD-L1 inhibitor and / or the vaccination time and follow-up information. 3. The healthy participants are not in an immunosuppressive state, such as cancer, HIV, autoimmune diseases, and long-term use of immunosuppressive drugs. 4. The healthy participants have exact vaccination time. 5. All participants have complete clinical and laboratory diagnostic data. 6. All participants are 18-75 years, regardless of gender. 7. All participants have agreed and signed the consent form before enrollment.
Exclusion criteria
1. Patients with unclear diagnosis of lung cancer were excluded. 2. Patients with incomplete clinical data or incomplete follow-up records. 3. Patients without signed informed consent. 4. Patient has received blood transfusion within three months. 5. Patients with HIV, Hepatitis B and Hepatitis C infections.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | June 2020- June 2023 (3 year) | OS is calculated as the time from PD-1/PD-L1 inhibitor starting to the death from any cause. |
| Antibody-dependent cellular cytotoxicity (ADCC) | Day 0 after vaccination | The ADCC activities of NK-92 cells cultured by the sera from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2. |
| Immune-related adverse events (irAEs) | June 2020- June 2023 | The performances and the grades of irAEs according to Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0) and their correlation with vaccination. |
| Progression-free Survival (PFS) | June 2020- June 2023 (3 year) | PFS is calculated as the time from from PD-1/PD-L1 inhibitor starting to the disease progression or the death from any cause. |
| Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM) | Day 0 after vaccination | The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA). |
| Titer of neutralization antibody | Day 0 after vaccination | Titer of neutralization antibody is measured by neutralization test. |
| Multiple chemokine and cytokine levels in peripheral blood | Day 0 after vaccination | IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay. |
| The numbers and proportions of T lymphocyte subpopulations in peripheral blood | Day 0 after vaccination | The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry. |
| Peripheral T cell activation and proliferation | Day 0 after vaccination | The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Control Rate (DCR) | June 2020- June 2023 (3 year) | The proportion of patients achieve CR or PR or stable disease (SD) after PD-1/PD-L1 inhibitor treatment according to RECIST 1.1. |
| Time to Treatment Failure (TFF) | June 2020- June 2023 (3 year) | The time from the start of PD-1/PD-L1 inhibitor to the withdrawal of the trial. The reasons for withdrawal include the patient's voluntary withdrawal, disease progression, adverse events and even deaths. |
| Objective Response Rate (ORR) | June 2020- June 2023 (3 year) | The proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases of complete response (CR) and partial response (PR) according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1). |
Countries
China
Contacts
Primary ContactYayi He
Outcome results
None listed